{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002682","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.636768+00:00","generated_at":"2026-06-07T02:31:06.697756+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Relay Therapeutics raises $30M in PIPE with Nextech; proceeds for RLY-2608 development","bullets":["2.5M shares sold at $12.00 each (premium to Jan 5 close); gross proceeds ~$30M.","PIPE expected to close Jan 10, 2024; Nextech Crossover I SCP is the investor.","Proceeds to advance RLY-2608 toward registrational trial(s) and preclinical pipeline.","Company plans to disclose at least one new Dynamo platform program later in 2024.","Resale registration statement to be filed within 15 business days."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002682","json":"https://secwatch.observer/filing/0000950170-24-002682.json","markdown":"https://secwatch.observer/filing/0000950170-24-002682.md","text":"https://secwatch.observer/filing/0000950170-24-002682.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/0000950170-24-002682-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/rlay-20240108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:31:06.697756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a359f7d26988c9dec4d459d60835d1fbcc0e24c1","claim":"Relay Therapeutics, Inc. entered into securities purchase agreement with Nextech Crossover I SCP valued at 2,500,000 shares at $12.00 per share for aggregate gross proceeds of approximately $30 million (effective 2024-01-08).","evidence_excerpt":"On January 8, 2024, Relay Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Nextech Crossover I SCP (the “Purchaser”), for the private placement (the “Private Placement”) of 2,500,000 shares (the “PIPE Shares”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), at $12.00 per share.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812364/000095017024002682/0000950170-24-002682-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Nextech Crossover I SCP"},{"label":"Value","value":"2,500,000 shares at $12.00 per share for aggregate gross proceeds of approximately $30 million"},{"label":"Effective","value":"2024-01-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}